Breast Cancer," Cleveland Clinic oncologist Tiffany Onger, MD, and host John Mangels continue their conversations on communicating effectively and empathetically with patients across the breast cancer ...
Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...
An open-label non–HLA-A*02 cohort showed a 0.7% annualized recurrence rate after primary immunization with GLSI-100, measured over an average 1.2 patient-years of exposure. Historical comparison to ...
A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with ...
The gut microbiome at time of surgery may significantly impact recurrence of colorectal cancer.An analysis of nearly 300 ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...
Women who previously had endometrial cancer and used vaginal estrogen therapy did not have higher risk for cancer recurrence than those who did not use vaginal hormone therapy, according to findings ...
What Is Recurrent Endometrial Cancer? Endometrial cancer is a type of cancer that starts in the lining of the uterus, called the endometrium. It's the most common form of gynecologic cancer in the ...
Despite the increased incidence of endometrial cancer in younger women, there is limited research regarding the safety of local, low-dose vaginal estrogen therapy (ET) for survivors. A new study ...
A custom NGS panel covering 27 IARC carcinogenic HPV genotypes enabled detection of ccfHPV DNA across treatment strata and supported recurrence-risk modeling adjusted for stage and tumor size.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results